Description
“These Statements Have Not Been Evaluated By The Food And Drug Administration. This Product Is Not Intended To Diagnose, Treat, Cure Or Prevent Any Disease.”
Product Specifications
- Product Name : Reta (Research Grade)
- CAS Number : 2381089-83-2
- Common Name : LY3437943
- Molecular Formula : C221H342N46O68
- Molecular Weight : 4731 g/mol
- Peptide Type : Triple-Hormone Receptor Agonist
- Target Receptors : GIP / GLP-1 / Glucagon (GCG)
- Purity : ≥99% (HPLC Verified)
- Form : Lyophilized White Powder
- Solubility : Soluble in sterile water or bacteriostatic water
- Endotoxin Level : Less than 1.0 EU/mg
Disclaimer : For Research Use Only (RUO). Not for human use.
Reta is a synthetic unimolecular peptide comprising 39 amino acids. Unlike dual agonists, it integrates activity at the Glucagon Receptor (GCGR) alongside GIP and GLP-1, creating a “Triple Synergy”.
Structure-Activity Relationship (SAR): The backbone is derived from GIP but modified to introduce Glucagon activity. It features a C20 fatty diacid moiety that binds to albumin, protecting the peptide from enzymatic degradation and extending its half-life to approximately 6 days.
Tuned Potency: Reta is designed with a specific hierarchy of potency: highest at GIP (for lipid buffering), moderate at GLP-1 (for satiety), and carefully tuned at Glucagon (to drive energy expenditure without hyperglycemia)
Regulatory & Compliance Statement
FDA Status : Reta is currently an Investigational New Drug (IND) in Phase 3 clinical trials (TRIUMPH & TRANSCEND series). It is not FDA-approved.
WADA Status : Prohibited under S2 (Peptide Hormones).
Usage : Strictly for Laboratory Research Use Only (RUO). Not for human use, diagnostic, or clinical procedures.
